YCANTH (VP-102) — Topline data
mid-2027
– Topline data from global Phase 3 program studying common warts currently expected in mid-2027 –Source filing
VRCA biotech catalysts & pipeline
VERRICA PHARMACEUTICALS INC · Data as of 2026-10-25
catalyst calendar
/